The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma
Standard
The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma : An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. / Cowan, Andrew J; Baldomero, Helen; Atsuta, Yoshiko; Mikhael, Joseph; Aljurf, Mahmoud; Seber, Adriana; Greinix, Hildegard; Koh, Mickey; Worel, Nina; Libby, Edward N; Pasquini, Marcelo; Galeano, Sebastian; Saber, Wael; Iida, Minako; Jaimovich, Gregorio; Rolon, Juliana Martinez; Kodera, Yoshihisa; Benakli, Malek; Nosa, Bazuaye G; Elhaddad, Alaa; Szer, Jeff; Passweg, Jakob; Kroeger, Nicolaus; Weisdorf, Daniel; Niederwieser, Dietger.
in: BIOL BLOOD MARROW TR, Jahrgang 26, Nr. 12, 12.2020, S. 2372-2377.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma
T2 - An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study
AU - Cowan, Andrew J
AU - Baldomero, Helen
AU - Atsuta, Yoshiko
AU - Mikhael, Joseph
AU - Aljurf, Mahmoud
AU - Seber, Adriana
AU - Greinix, Hildegard
AU - Koh, Mickey
AU - Worel, Nina
AU - Libby, Edward N
AU - Pasquini, Marcelo
AU - Galeano, Sebastian
AU - Saber, Wael
AU - Iida, Minako
AU - Jaimovich, Gregorio
AU - Rolon, Juliana Martinez
AU - Kodera, Yoshihisa
AU - Benakli, Malek
AU - Nosa, Bazuaye G
AU - Elhaddad, Alaa
AU - Szer, Jeff
AU - Passweg, Jakob
AU - Kroeger, Nicolaus
AU - Weisdorf, Daniel
AU - Niederwieser, Dietger
N1 - Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Multiple myeloma (MM) is a plasma cell neoplasm characterized by destructive bony lesions, anemia, and renal impairment. Access to effective therapy is limited globally. We report the rates and utilization of hematopoietic cell transplantation (HCT) globally from 2006-2015 to better characterize access to HCT for patients with MM. This was an analysis of a retrospective survey of Worldwide Network of Blood and Marrow Transplant sites, conducted annually between 2006-2015. Incidence estimates were from the Global Burden of Disease study. Outcome measures included total number of autologous and allogeneic HCTs by world regions, and percentage of newly diagnosed MM patients who underwent HCT, calculated by the number of transplants per region in calendar year/gross annual incidence of MM per region. From 2006 to 2015, the number of autologous HCT performed worldwide for MM increased by 107%. Utilization of autologous HCT was highest in Northern America and European regions, increasing from 13% to 24% in Northern America, and an increase from 15% to 22% in Europe. In contrast, the utilization of autologous HCT was lower in the Africa/Mediterranean region, with utilization only changing from 1.8% in 2006 to 4% in 2015. The number of first allogeneic HCT performed globally for MM declined after a peak in 2012 by -3% since 2006. Autologous HCT utilization for MM has increased worldwide in high-income regions but remains poorly utilized in Africa and the East Mediterranean. More work is needed to improve access to HCT for MM patients, especially in low to middle income countries. © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
AB - Multiple myeloma (MM) is a plasma cell neoplasm characterized by destructive bony lesions, anemia, and renal impairment. Access to effective therapy is limited globally. We report the rates and utilization of hematopoietic cell transplantation (HCT) globally from 2006-2015 to better characterize access to HCT for patients with MM. This was an analysis of a retrospective survey of Worldwide Network of Blood and Marrow Transplant sites, conducted annually between 2006-2015. Incidence estimates were from the Global Burden of Disease study. Outcome measures included total number of autologous and allogeneic HCTs by world regions, and percentage of newly diagnosed MM patients who underwent HCT, calculated by the number of transplants per region in calendar year/gross annual incidence of MM per region. From 2006 to 2015, the number of autologous HCT performed worldwide for MM increased by 107%. Utilization of autologous HCT was highest in Northern America and European regions, increasing from 13% to 24% in Northern America, and an increase from 15% to 22% in Europe. In contrast, the utilization of autologous HCT was lower in the Africa/Mediterranean region, with utilization only changing from 1.8% in 2006 to 4% in 2015. The number of first allogeneic HCT performed globally for MM declined after a peak in 2012 by -3% since 2006. Autologous HCT utilization for MM has increased worldwide in high-income regions but remains poorly utilized in Africa and the East Mediterranean. More work is needed to improve access to HCT for MM patients, especially in low to middle income countries. © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
U2 - 10.1016/j.bbmt.2020.08.018
DO - 10.1016/j.bbmt.2020.08.018
M3 - SCORING: Journal article
C2 - 32846200
VL - 26
SP - 2372
EP - 2377
JO - BIOL BLOOD MARROW TR
JF - BIOL BLOOD MARROW TR
SN - 1083-8791
IS - 12
ER -